The most commonly reported side effects of peginesatide include dyspnoea, nausea, and vomiting, based on 211 FDA adverse event reports from 2012 to 2016.
Percentages show how often each reaction appears relative to total reports for peginesatide.
These are voluntary reports and do not establish that peginesatide caused these reactions.
Report severity
Seriousness is determined by the reporter, not by OpenClaim.
Other drugs that appear in adverse event reports alongside peginesatide. Drugs flagged as a suspected cause appear in the first column. Drugs taken at the same time but not suspected appear in the second.
Also suspected
Taken alongside
Co-occurrence in adverse event reports does not establish a drug interaction. Patients often take multiple medications, and these lists reflect prescribing patterns rather than causal relationships. Consult a healthcare provider about potential drug interactions.
43.6% of peginesatide adverse event reports involve female patients and 47.4% involve male patients. The largest age group is adult at 61%. These figures reflect who reports side effects, not underlying risk.
Sex
Age group
Conditions and purposes for which patients were taking peginesatide when the adverse event was reported.
Peginesatide is sold under the brand name Omontys Preservative Free.
An upward trend reflects increased FAERS reporting overall, not necessarily increased risk.
Ask OpenClaim about your specific drug combination. Get a sourced report using FDA data, drug labels, and medical literature.